Siemens Healthineers Announces Collaboration Agreement for Assay Development With an Initial Focus on Multiple Sclerosis

BERKELEY, Calif.--(BUSINESS WIRE)--Siemens Healthineers announced today a master collaboration agreement with Novartis Pharma AG to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis’ therapeutic pipeline. The initial program assists the development of a serum NfL immunoassay to support Novartis’ MS and other neuroscience programs. NfL is a highly specific biomarker for nerve cell injury measured in cerebral spinal fluid and blood. Blood NfL levels have